Suppression of pathological ocular neovascularization by a small molecule, SU1498 - 18/06/20
, Yan Biao c, d, e, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | SU1498 has no obvious cytotoxicity and tissue toxicity. |
• | SU1498 administration suppresses ocular angiogenesis in vivo. |
• | SU1498 administration inhibits endothelial angiogenic function in vitro. |
• | SU1498 regulates endothelial function through p38-MAPK signaling. |
Abstract |
Selective inhibition of vascular endothelial growth factor receptor (VEGFR), particularly VEGFR-2, is an efficient method for the treatment of ocular neovascularization. SU1498 is a specific inhibitor of VEGFR-2. In this study, we investigated the role of SU1498 in ocular neovascularization. Administration of SU1498 did not show any cytotoxicity and tissue toxicity at the tested concentrations. Administration of SU1498 reduced the size and thickness of choroidal neovascularization and decreased the mean length and mean number of corneal neovascular vessels induced by alkali burn. Pretreatment of SU1498 significantly reduced the proliferation, migration, and tube formation ability of HUVECs. SU1498 played the anti-angiogenic role through the regulation of p38-MAPK signaling. Taken together, inhibition of VEGFR-2 by SU1498 provides a novel therapeutic approach for ocular neovascularization.
Le texte complet de cet article est disponible en PDF.Keywords : Ocular neovascularization, VEGFR-2 inhibitor, MAPK signaling
Plan
Vol 128
Article 110248- août 2020 Retour au numéro
Article précédent
- Activation of SREBP-1c alters lipogenesis and promotes tumor growth and metastasis in gastric cancer
- Qianqian Sun, Xiaojuan Yu, Chunwei Peng, Ning Liu, Wentong Chen, Hu Xu, Hongquan Wei, Kun Fang, Ziwei Dong, Chuyu Fu, Youzhi Xu, Wenjie Lu
- The synergistic effect of NELL1 and adipose-derived stem cells on promoting bone formation in osteogenesis imperfecta treatment
- Yi Liu, Mingyan Ju, Zihan Wang, Jiaci Li, Chenyi Shao, Ting Fu, Yaqing Jing, Yuxia Zhao, Zhe Lv, Guang Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?